[Percutaneous radiofrequency ablation of XXXX : Update 2015].

@entity1 @entity5 @entity1358 @entity3 @entity703
BACKGROUND: @entity1358 is a @entity5 with a relatively good prognosis. The incidence of all @entity1358 is approximately 9/100,000 @entity1 . There are nearly 15,000 newly diagnosed @entity1 every year ( @entity1 twice as often as @entity1 ). TREND: In the last decade, a trend away from radical open resection towards nephron-sparing approaches has been observed. Currently, partial nephrectomy is the surgical gold standard for the treatment of small @entity703 . However, excellent clinical results are obtained using percutaneous radiofrequency ablation (RFA): low complication rates and preservation of the renal function. RESULTS: Primary and secondary technical success rates are 69-100% and 90-100%, respectively. In large series, major complication rates of RFA of 0-14% are reported. A relevant deterioration of renal function after RFA is very rare. The 5-year local recurrence-free survival rates, @entity3 -free survival rates, @entity5 -specific survival rates, and overall survival rates are 88-93, 95-100, 98-100, and 58.3-85%, respectively. In this context, the lack of appropriate long-term data is often cited as a limitation. CONCLUSION: Different meta-analyses come to the conclusion that in case of adequate @entity5 and @entity1 selection RFA shows oncologic results comparable with surgical resection. Accepted indications for RFA are T1  @entity703 in @entity1 with advanced age, significant comorbidities, reduced renal function, single kidney, and/or no wish for operation. Predictors for the success include @entity5 size and location as well as operator experience. To define the real efficacy of RFA in the treatment of @entity703 , randomized controlled clinical long-term studies are indicated.
